Assessing New Therapies for Retinal Diseases

Opinion
Video

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Video content above is prompted by the following:

  • New Therapies:
  • Aflibercept 8 mg
Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Related Content
An illustration of kidneys, in black-and-white, with color over some sections to indicate disease. Image credit: ©Crystal light – stock.adobe.com

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

Hattie Hayes
February 20th 2025
Article

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A crystal ball sits on a small platform, surrounded by misty fog. ©alexkich – stock.adobe.com

Retinal biomarkers in OCT imaging may have predictive applications for nAMD

Lynda Charters
February 17th 2025
Article

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A man wearing Nuance Audio hearing aid glasses speaks to a friend. Image courtesy of EssilorLuxottica

Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval

Emily Kaiser Maharjan
February 4th 2025
Article

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.